12 Results for "

Primate model

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "Primate model" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-P1717
CAS No.: 1427001-89-5
Synonyms: Cp40
Research Areas:  

Inflammation/Immunology

AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
8
8 Publications Verification
Cat. No.: HY-P1717B
Synonyms: Cp40 acetate
Research Areas:  

Inflammation/Immunology

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
8
8 Publications Verification
Cat. No.: HY-P1717A
CAS No.: 1789738-04-0
Synonyms: Cp40 TFA
Research Areas:  

Inflammation/Immunology

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-138171
CAS No.: 2089251-33-0
Purity:  99.50%
Target:  

Liposome

Research Areas:  

Others

Lipid 5 is an amino lipid that affords efficient mRNA delivery in rodent and primate models. Lipid 5 shows optimal pharmacokinetics and non-toxic side effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-12700
CAS No.: 1043495-96-0
Purity:  98.75%
RO5256390 is an orally effective trace amine associated receptor 1 (TAAR1) agonist. RO5256390 exhibits pro-cognitive and antidepressant-like properties in rodent and primate models, showing similar brain activation patterns to Olanzapine (HY-14541). RO5256390 blocks compulsive overeating behavior in rats. RO5256390 can inhibit ATP (HY-B2176)-induced TNF secretion in mouse bone marrow-derived macrophages .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99302
CAS No.: 2235419-62-0
Synonyms: BMS-931699 Antibody

Target:  

CD28

Research Areas:  

Inflammation/Immunology

Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
loading...
    loading...
Cat. No.: HY-P99916
CAS No.: 2449199-61-3
Synonyms: AMG 427
Target:  

FLT3 CD3 TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .
loading...
    loading...
Cat. No.: HY-14555
CAS No.: 245514-32-3
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

S33138 is a D3 receptor antagonist. S33138 inhibits addiction in animal models of addiction. S33138 reduces cognitive impairment in rodent and primate models of schizophrenia and Parkinson's disease. S33138 can be used in research on neurological disorders such as schizophrenia and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-P991547
CAS No.: 922534-56-3

Target:  

CD20 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies .
loading...
    loading...
Cat. No.: HY-P991467

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

RG-7258 is a human monoclonal antibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .
loading...
    loading...
Cat. No.: HY-176522
Research Areas:  

Cancer

Oligomer-lipid 7C1 is an ionazable lipid. Oligomer-lipid 7C1 can be generated through the reaction of low-molecular-weight polyamine with lipid. Oligomer-lipid 7C1 efficiently binds siRNA to form nanoparticle. Oligomer-lipid 7C1 can induce RNA interference in endothelial cells of multiple organs in nonhuman primates. Oligomer-lipid 7C1 is able to deliver siRNA to endothelial cells and facilitates endothelial function modification in mouse models of vascular permeability, emphysema, primary tumor growth and metastasis .
loading...
    loading...
Cat. No.: HY-P992369

Target:  

VISTA

Research Areas:  

Cancer

HMBD-002 is an Fc-independent, non-depleting IgG4 subclass antibody that targets VISTA and VSIG3. It is widely used in research related to various solid tumors, including colon cancer, triple-negative breast cancer, and non-small cell lung cancer. HMBD-002 blocks the interactions of VISTA with VSIG3 and LRIG1, relieves immunosuppression without depleting VISTA-positive cells, activates the cytotoxic program of CD8 + T cells, and drives the type I interferon signaling pathway. HMBD-002 reprograms tumor-associated macrophages to the M1 phenotype, reduces tumor infiltration of inhibitory myeloid cells, thereby significantly inhibiting tumor growth and improving survival. HMBD-002 is well tolerated in rodent and non-human primate animal models .
loading...
    loading...
  • 1